Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 15, 2021 07:00 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Two Phase 3 studies to enroll a total of 300 patients in assisted living or residential facilities and nursing homes to evaluate the safety and efficacy of BXCL501 Studies designed to maximize...
December 01, 2021 07:00 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

PDUFA date extended by three months to April 5, 2022 No Additional Data Requested Following Meeting with FDA NEW HAVEN, Conn., Dec. 01, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq:...
November 11, 2021 07:00 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics to Present at the 2021 Jefferies London Healthcare Conference

NEW HAVEN, Conn., Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
November 10, 2021 07:00 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Operational Highlights

Plans for commercial and launch readiness advancing for BXCL501 orally dissolving film, for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, ahead of...
October 27, 2021 07:00 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021

NEW HAVEN, Conn., Oct. 27, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
October 18, 2021 07:00 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer

Initial findings from Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent Small-Cell...
September 23, 2021 07:00 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day

Management to showcase AI platform to develop potential treatments for neuropsychiatric disorders Company to introduce BXCL502 program and discuss expansion opportunities for lead program, BXCL501 ...
September 15, 2021 18:06 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO

BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma BXCL701 combination continues to exhibit favorable safety...
September 12, 2021 18:05 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
September 09, 2021 07:00 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021

Live webcast, Revolutionizing Drug Discovery and Development Through AI, to be held from 12:00 PM ET – 2:00 PM ET NEW HAVEN, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc....